Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Prognostic Value of the HCT Comorbidity Index
Biol Blood Marrow Transplant; ePub 2017 Feb 8; Salit, et al
Hematopoietic cell transplantation comorbidity index (HCT-CI) >3 is linked with an increased risk of treatment related mortality 3 years after transplant in people undergoing reduced intensity conditioning (RIC) cord blood transplantation (CBT), according to a study involving 151 individuals.
Participants had acute myeloid leukemia/myelodysplastic syndrome (n=101), chronic myeloid leukemia (n=3), acute lymphoblastic leukemia (n=24), non-Hodgkin lymphoma (n=8), Hodgkin lymphoma (n=3), or other hematologic malignancies (n=12) and underwent RIC CBT. All received cyclosporine and mycophenolate mofeteil for graft versus host disease prophylaxis. Among the results:
- Overall median HCT-CI was 3.
- There was no significant difference in treatment related mortality in low-, medium- and high-risk HCT-CI groups.
- When patients were divided into 2 groups, treatment-related mortality 3 years after transplant was 26% in the HCT-CI ≤3 group, and 50% in the HCT-CI >3 group.
- Overall survival in the ≤3 group was 40%, vs 29% >3 contingent.
Salit R, Oliver D, Delaney C, Sorror M, Milano F. Prognostic value of the hematopoietic cell transplant comorbidity index for patients undergoing reduced intensity conditioning cord blood transplantation. [Published online ahead of print February 8, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.01.084.